At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
MSC2156119Jdrug
Likely dose
MSC2156119J 215 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating MSC2156119J for Solid Tumors. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartApr 2013
Primary CompletionMar 2014
Study CompletionOct 2014
TodayJul 2026
First PostedApr 16, 2013
Enrollment StartApr 30, 2013
Primary CompletionMar 31, 2014
Study CompletionOct 31, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.2 years ago
Interventions
MSC2156119Jdrug
Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.